• Ariëns EJ, Van Rossum JM, Simonis AM (1959). A theoretical basis of molecular pharmacology. Part III: Interaction of one or two compounds with two independent receptor systems. Arzneirn Forsch 6: 737746.
  • Black JW, Duncan WAM, Durant GJ, Ganellin CR, Parsons ME (1972). Definition and antagonism of histamine H2-receptors. Nature Lond 236: 385390.
  • Black JW, Duncan WAM, Emmett JC, Ganellin CR, Hesselbo T, Parsons ME, Wyllie JH (1973). Metimnide – an orally active histaminie H2-receptor antagonist. Agents and Actions 3: 133137.
  • Burn JH, Dale HH (1926). The vasodilator action of hiistaminc and its physiological significance. J Physiol Lond 61: 185214.
  • Dale HH, Laidlaw PP (1910). The physiological action of beta-imidazolylethylamine. J Physiol Lond 41: 318344.
  • Emmelin N, Muren A (1949). Effects of anti-histamine compounds on the adrenaline liberation from the suprarenals. Acta physiol Scand 17: 345355.
  • Folkow B, Haeger K, Kahlson G (1948). Observations on reactive hyperaemia as related to histamine on drugs antagonising vasodilation induced by histamine and on vasodilator properties of adenosinetriphosphate. Acta physiol Scand 15: 264278.
  • Owen DAA, Parsons ME (1974). Histamine receptors in the cardiovascular system of the cat. Br J Pharmac 51: 123P124P.
  • Staub AM (1939). Recherches sur quelques bases synthetiques antagonistes de l’histamine. Ann Inst Pasteur 63: 400436.